Skip to main content

Covalent Organic Framework Nanofilm-Assisted Laser Desorption Ionization Mass Spectrometry for the Determination of Benzophenone Derivatives in Personal Care Products.

Rapid communications in mass spectrometry : RCM2025-02-14PubMed
Total: 72.0Innovation: 8Impact: 7Rigor: 6Citation: 9

Summary

A TAPB-DMTP COF nanofilm used as an LDI-MS substrate yields stronger signals and cleaner backgrounds than standard organic matrices for small molecules. The method quantifies BP-1 in personal care products with excellent linearity (1–20 μg/mL, r=0.9993), low LOD (0.3 μg/mL), robust reproducibility (RSD 6.10%), and 30-day stability, supporting sensitive surveillance of endocrine-disrupting UV filters.

Key Findings

  • COF nanofilm-assisted LDI-MS produced stronger signals and cleaner backgrounds than CHCA, DHB, and SA for small-molecule analysis.
  • Demonstrated high reproducibility (RSD 6.10%) and stability up to 30 days.
  • Quantified BP-1 with excellent linearity (1–20 μg/mL, r=0.9993), low LOD (0.3 μg/mL), and recoveries of 94.2%–104.4% in personal care products.

Clinical Implications

Supports faster, more reliable screening of endocrine-disrupting UV filters in personal care products, informing regulatory compliance, product reformulation, and public health risk assessment.

Why It Matters

Provides a practical, scalable analytical platform for detecting benzophenone UV filters in complex cosmetic matrices, enabling regulatory monitoring and exposure assessment. The COF-LDI-MS approach is broadly applicable to other small molecules beyond cosmetics.

Limitations

  • Focused quantification on BP-1; broader validation across more benzophenones and other UV filters is needed.
  • Single-laboratory evaluation without inter-lab reproducibility studies.

Future Directions

Extend the COF-LDI-MS platform to a panel of UV filters and cosmetic additives; conduct inter-lab validation and standardize protocols for regulatory adoption.

Study Information

Study Type
Case series
Research Domain
Diagnosis
Evidence Level
V - Method development and validation study without clinical subjects.
Study Design
OTHER